Net sales and EBIT surged in H1 2026, driven by strong Americas performance and a one-off customs refund. Safety segment excelled, while medical faced tough prior-year comparisons. FY 2026 guidance was raised for EBIT margin and confirmed for sales growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.